Get the Stockscreener App
12.53
6.01%
0.71
After Hours:
12.49
-0.04
-0.32%
Phathom Pharmaceuticals Inc stock is traded at $12.53, with a volume of 1.01M.
It is up +6.01% in the last 24 hours and up +5.83% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$11.82
Open:
$11.77
24h Volume:
1.01M
Relative Volume:
0.89
Market Cap:
$888.92M
Revenue:
$114.04M
Net Income/Loss:
$-330.15M
P/E Ratio:
-2.649
EPS:
-4.73
Net Cash Flow:
$-274.85M
1W Performance:
+7.92%
1M Performance:
+5.83%
6M Performance:
+156.76%
1Y Performance:
-16.96%
1-Day Range:
$11.63
$12.57
1-Week Range:
$10.33
$12.57
52-Week Range:
$2.21
$19.50
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
12.53 | 838.55M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
How sentiment analysis helps forecast Phathom Pharmaceuticals Inc.2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Does Phathom Pharmaceuticals Inc. fit your quant trading modelWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Is Phathom Pharmaceuticals Inc. stock a buy on dips2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com
Using economic indicators to assess Phathom Pharmaceuticals Inc. potentialJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 2025Market Growth Review & Consistent Profit Focused Trading Strategies - newser.com
Statistical indicators supporting Phathom Pharmaceuticals Inc.’s strength2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8%Still a Buy? - MarketBeat
Will Phathom Pharmaceuticals Inc. continue its uptrendDay Trade & AI Powered Market Trend Analysis - newser.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Is Phathom Pharmaceuticals Inc. meeting your algorithmic filter criteriaJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
Leading vs lagging indicators on Phathom Pharmaceuticals Inc. performanceMarket Performance Report & Long-Term Capital Growth Strategies - newser.com
Why hedge funds are buying Phathom Pharmaceuticals Inc. stockJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Phathom Pharmaceuticals Hits Day Low of $10.33 Amid Price Pressure - Markets Mojo
When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Breakeven? - simplywall.st
Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 7.8%Here's What Happened - MarketBeat
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer - citybiz
Phathom Pharmaceuticals, Inc. Appoints Sanjeev Narula as Chief Financial and Business Officer - MarketScreener
When is the best time to exit Phathom Pharmaceuticals Inc.Global Markets & Expert Approved Trade Ideas - newser.com
Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer - Investing.com
Phathom Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial and business officer - Investing.com
Using Bollinger Bands to evaluate Phathom Pharmaceuticals Inc.2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Analyzing recovery setups for Phathom Pharmaceuticals Inc. investorsSwing Trade & Long-Term Safe Investment Ideas - newser.com
Will Phathom Pharmaceuticals Inc. see short term momentumQuarterly Growth Report & Low Drawdown Trading Strategies - newser.com
Tools to monitor Phathom Pharmaceuticals Inc. recovery probabilityJuly 2025 Summary & Safe Capital Preservation Plans - newser.com
How to integrate Phathom Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
How Phathom Pharmaceuticals Inc. stock reacts to Fed rate cutsQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
What Fibonacci levels say about Phathom Pharmaceuticals Inc. reboundMarket Risk Report & Daily Stock Momentum Reports - newser.com
How to build a custom watchlist for Phathom Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-02 20:30:06 - newser.com
Phathom Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo
Published on: 2025-10-01 09:34:59 - newser.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 5.5%Still a Buy? - MarketBeat
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):